Recombinant Human Albumin(Oryza sativa) Selected into List of Landmark Biomanufacturing Products by the Ministry of Industry and Information Technology of the People's Republic of China

On July 31, 2025, the Ministry of Industry and Information Technology of the People's Republic of China announced the first batch list of landmark biomanufacturing products list for 2024. A total of 36 landmark products cover multiple sub-fields such as biomaterials, biochemical engineering and biomedicine, fully demonstrating China’s cutting-edge technological achievements in bio-manufacturing and setting a benchmark for future industrial development. Healthgen Biotech’s newly approved product-Recombinant Human Albumin Injection (Oryza sativa) has been successfully selected in the list, showcasing the outstanding R&D capabilities and market competitiveness in the biopharmaceutical area.

News link:

https://www.miit.gov.cn/zwgk/wjgs/art/2025/art_aab6125932a24f92811fa44140001717.html

It is reported that the collection of the landmark biomanufacturing products aims to implement the spirit of the National Conference on Promoting New Industrialization, drive original and disruptive technological breakthroughs and promote the application of landmark products in the biomanufacturing field. It also aims to accelerate the conversion of innovative achievements into real productivity and enhance the integrated development capabilities of biomanufacturing in the “technology research and development-production and manufacturing- market promotion”chain. The "First Batch of Landmark Biomanufacturing Products List" was formed through procedures such as recommendations from provincial competent departments of industry and information technology and expert review and evaluation.

As the first approved Recombinant Human Albumin Injection in China, and the world’s first  recombinant human albumin using a plant expression system. Recombinant Human Albumin Injection(Oryza sativa) has overcome challenges associated with recombinant technology,such as low production yields, complex purification processes, difficulties in scaling up production, high safety risks, and high costs.The launch of Recombinant Human Albumin Injection(Oryza sativa) signifies that China has taken a leading position internationally in the research and development of recombinant human albumin and plant bioreactor technology, breaking the long-standing reliance on imported human serum albumin. This achievement holds significant strategic importance and social value.